Skip to search formSkip to main contentSkip to account menu

APF530

Known as: APF-530 
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Effect of APF530 on health-related quality of life (QOL) and other chemotherapy-induced nausea and vomiting (CINV) end points: Phase III MAGIC trial.
e21666Background: Delayed (24-120 h) CINV after highly emetogenic chemotherapy (HEC) is a clinical challenge, negatively… 
2016
2016
Phase III MAGIC trial of APF530 v ondansetron (Ond) with fosaprepitant (Fos) + dexamethasone (Dex) for highly emetogenic chemotherapy (HEC)-induced nausea and vomiting: analysis by age and gender.
e21700Background: In a large (N = 902) phase III trial (MAGIC), APF530 (granisetron, extended release), showed superior complete… 
2016
2016
Abstract P1-10-07: Phase 3 comparison of APF530 versus ondansetron, each in a guideline-recommended 3-drug regimen for prevention of chemotherapy-induced nausea and vomiting due to anthracycline…
Background: Managing delayed chemotherapy-induced nausea and vomiting (CINV) associated with HEC is an unmet need. AC-based HEC… 
2016
2016
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly…
APF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h) chemotherapy… 
2015
2015
Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained… 
2015
2015
with APF530 (sustained-relea se granisetron)
2014
2014
Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC…
9645 Background: APF530 provides controlled, sustained release of granisetron for preventing acute (0-24 h) and delayed (24-120 h… 
2013
2013
Recovery of complete antiemetic response with APF530 during treatment with moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens in patients who failed palonosetron.
e20569 Background: Several 5-HT3 antagonists are available to prevent chemotherapy-induced nausea and vomiting (CINV); when… 
Review
2010
Review
2010
FDA Pipeline preview, April 2010 (Miglustat, Insulin human inhalation powder, APF530, Exenatide LAR, Pirfenidone, ACU-4429, L-asparaginase, Alpha1-proteinase inhibitor, LIPO-102, QPI-1002/I5NP, MA09…
Recent FDA action (through March 2010) related to Miglustat, Insulin human inhalation powder, APF530, Exenatide LAR, Pirfenidone… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)